Kohei Shitara

Antibody-drug conjugates in the treatment of solid tumors 3:23
Antibody-drug conjugates in the treatment of solid tumors
Kohei Shitara • 3 Jun 2023
Claudin 18.2: a biomarker for gastric cancer 1:07
Claudin 18.2: a biomarker for gastric cancer
Kohei Shitara • 3 Jun 2023
IILUSTRO: zolbetuximab, mFOLFOX6, and nivolumab combinations for gastrointestinal cancer 1:52
IILUSTRO: zolbetuximab, mFOLFOX6, and nivolumab combinations for gastrointestinal cancer
Kohei Shitara • 3 Jun 2023
Novel treatments for gastric cancer 1:03
Novel treatments for gastric cancer
Kohei Shitara • 3 Jun 2023
Assessing the prevalence of CLDN18.2 in gastric/gastroesophageal cancers 1:35
Assessing the prevalence of CLDN18.2 in gastric/gastroesophageal cancers
Kohei Shitara • 5 Jun 2023
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC 2:42
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC
Kohei Shitara • 19 Jan 2023
SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer 2:49
SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer
Kohei Shitara • 19 Jan 2023
3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC 1:22
3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC
Kohei Shitara • 19 Jan 2023
Which patients with gastric cancer can benefit most from checkpoint inhibitors? 1:54
Which patients with gastric cancer can benefit most from checkpoint inhibitors?
Kohei Shitara • 25 Nov 2022
Clinical trials investigating immunotherapy for gastric cancer 2:12
Clinical trials investigating immunotherapy for gastric cancer
Kohei Shitara • 25 Nov 2022
Predictive biomarkers for immunotherapy in upper GI cancers 5:16
Predictive biomarkers for immunotherapy in upper GI cancers
Kohei Shitara • 25 Nov 2022
Advances in HER2-targeted therapies for gastric cancer 3:12
Advances in HER2-targeted therapies for gastric cancer
Kohei Shitara • 12 Sep 2022
KEYNOTE-061: association between gene expression signatures & outcomes 1:35
KEYNOTE-061: association between gene expression signatures & outcomes
Kohei Shitara • 12 Sep 2022
Gastric cancer updates at ESMO 2022 1:14
Gastric cancer updates at ESMO 2022
Kohei Shitara • 12 Sep 2022
LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma 2:44
LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma
Kohei Shitara • 12 Sep 2022
Rationale and study design of CheckMate-649 biomarker analysis 4:21
Rationale and study design of CheckMate-649 biomarker analysis
Kohei Shitara • 14 Apr 2022
The content of VJOncology is intended for healthcare professionals